An open label, multi-centre, non-randomized, single arm study to evaluate the safety and efficacy of APCEDEN? [Dendritic Cell (DC) immunotherapy] in patients with refractory solid malignancies, on symptomatic treatment. - ATESST (Apceden Therapy: Efficacy and Safety in Solid Tumors)

Start Date14 Sep 2011

Sponsor / Collaborator

Semler Research Center, Inc.

100 Clinical Results associated with Autologous dendritic cell immunotherapy (APAC Biotech)

100 Translational Medicine associated with Autologous dendritic cell immunotherapy (APAC Biotech)

100 Patents (Medical) associated with Autologous dendritic cell immunotherapy (APAC Biotech)

Literatures (Medical) associated with Autologous dendritic cell immunotherapy (APAC Biotech)

01 Dec 2019·Future Science OA

Substantial Remission of Prostate Adenocarcinoma With Dendritic Cell Therapy APCEDEN ^® in Combination With Chemotherapy

Author: Bagga, Jasmine ; Bharadwaj, Asmi ; Inamdar, Shriram ; Kohli, Sakshi ; Chiliveru, Srikanth ; Kumar, Chaitanya ; Sharan, Bandana ; Jain, Minish

Of the most prevalent solid tumors with advanced disease, prostate and ovarian cancer and non-small cell lung carcinoma have the fewest therapeutic options. Herein, we report the case of a 63-year-old male with metastatic prostate adenocarcinoma showing substantial remission post-administration of personalized dendritic cell-based vaccine APCEDEN® in combination with chemotherapeutic drug Mitoxantrone. Therapeutic response displayed an interesting clinical correlation validated by PET scan images showing decreased fluorodeoxyglucose (FDG) avidity in the prostate gland, reduced skeletal metastases further established by the drop in serum Prostate Specific Antigen (PSA) levels and expression of immune assessment markers (IFN-γ, Tregs, neutrophil lymphocyte ratio and platelet lymphocyte ratio). This case demonstrates the potential efficacy of dendritic cell immunotherapy, showing a potent antitumor activity by enhancing the host immune responses, and improving quality of life.

01 Oct 2017·Clinical Case Reports

Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN^® (dendritic cell‐based vaccine): a case report

Author: Sharan, Bandana ; Kohli, Sakshi ; Jain, Minish ; Chiliveru, Srikanth ; Kumar, Chaitanya

Key Clinical Message

APCEDEN

® is an autologous monocyte‐derived dendritic cell‐based immunotherapy. A 58‐year‐old man with adenocarcinoma of oropharynx shows complete remission after receiving APCEDEN® in conjunction with Geftinib validated by reduction in size, whereas Gefitinib alone lead to disease progression.

01 Sep 2017·ImmunotherapyQ4 · MEDICINE

A Retrospective Analysis Comparing APCEDEN ^® Dendritic Cell Immunotherapy with Best Supportive Care in Refractory Cancer

Q4 · MEDICINE

Article

Author: Mohan, Jagan ; Kohli, Sakshi ; Suresh Attili, Venkata Sathya ; Sharan, Bandana ; Chiliveru, Srikanth ; Bapsy, Poonamalle Parthasarathy ; Kumar, Chaitanya ; Vaid, Ashok K ; Jain, Minish

Aim: A retrospective survival benefit analysis of APCEDEN®, APAC BIOTECH Pvt Ltd 69, Jacranda Marg, DLF PHASE II, Gurugram, Haryana, India, an autologous dendritic cell-based product for management of refractory solid malignancies, was performed in comparison with a control group. Methods: Subjects (retrospective data) whose survival data, geographical region, age, gender, ECOG performance status and stage of disease that could be matched with the treatment group were considered for analysis. Results: The analysis suggests a significant survival benefit of 199 days for the APCEDEN therapy treatment group when compared with the control group (356 vs 157 days). The event-free survival time of APCEDEN therapy was 439 days in patients who demonstrated an objective response at first evaluation as per immune-related response criteria. Conclusion: APCEDEN demonstrated highly convincing survival benefits when compared with the control group.

100 Deals associated with Autologous dendritic cell immunotherapy (APAC Biotech)

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ovarian Epithelial Carcinoma	India	APAC Biotech Pvt Ltd.	07 Jul 2019
Prostatic Cancer	India	APAC Biotech Pvt Ltd.	06 Jul 2019
Colorectal Cancer	India	APAC Biotech Pvt Ltd.	03 Jul 2019
Non-Small Cell Lung Cancer	India	APAC Biotech Pvt Ltd.	27 Jun 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioblastoma	Phase 2	India	APAC Biotech Pvt Ltd.	-
Renal Cell Carcinoma	Phase 2	India	APAC Biotech Pvt Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Autologous dendritic cell immunotherapy (APAC Biotech)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation